7020 Influenza A M2 transmembrane domain
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Organic nitrogen compounds | 2 | 0.1 | 16× | not tested | |
| Homogeneous non-metal compounds | 4 | 0.9 | 4.71× | not tested | |
| Lipids and lipid-like molecules | 1 | 0.4 | 2.28× | not tested | |
| Homogeneous metal compounds | 1 | 1.9 | 0.52× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
No DrugBank compounds are annotated on this group's domains.
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CL | CHLORIDE ION | 39 |
| RIM | RIMANTADINE | 24 |
| E01 | (1r,1'S,3'S,5'S,7'S)-spiro[cyclohexane-1,2'-tricyclo[3.3.1.1~3,7~]decan]-4-amine | 16 |
| EU7 | (1S)-1-[(3R,5R,7R)-tricyclo[3.3.1.1~3,7~]decan-1-yl]ethan-1-amine | 16 |
| 3LW | (3s,5s,7s)-N-[(5-bromothiophen-2-yl)methyl]tricyclo[3.3.1.1~3,7~]decan-1-aminium | 8 |
| CAmetal | CALCIUM ION | 8 |
| OLC | (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate | 8 |
| A2Y | (3S,5S,7S)-N-{[5-(thiophen-2-yl)-1,2-oxazol-3-yl]methyl}tricyclo[3.3.1.1~3,7~]decan-1-aminium | 4 |
| 308 | (3S,5S,7S)-tricyclo[3.3.1.1~3,7~]decan-1-amine | 1 |